Optimizing the treatment of chronic viral hepatitis C

Expert Review of Gastroenterology and Hepatology

Volumn 3, Issue 6, 2009, Pages 607-613

  François, Catherine ^a   Castelain, Sandrine ^b   Duverlie, Gilles ^b   Capron, Dominique ^c   Nguyen Khac, Eric ^b  

^a UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

^b AMIENS UNIVERSITY HOSPITAL   (France)

^c UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

Author keywords

Hepatitis C; Hepatitis C treatment; Hepatitis C virus; Interferon; Ribavirin

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ANTIVIRUS AGENT; BOCEPREVIR; ERYTHROPOIETIN; NITAZOXANIDE; PEGINTERFERON; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; POLYMERASE INHIBITOR; PROTEINASE INHIBITOR; RIBAVIRIN; TELAPREVIR; UNCLASSIFIED DRUG; VIRUS RNA;

ANEMIA; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TREATMENT FAILURE; FATTY LIVER; GENE FUNCTION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAINTENANCE THERAPY; MONOTHERAPY; NONHUMAN; REFERENCE VALUE; RELAPSE; REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS GENE; VIRUS LOAD; VIRUS STRAIN; VIRUS TRANSMISSION;

ANTIVIRAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; POLYETHYLENE GLYCOLS; RIBAVIRIN; TREATMENT OUTCOME;

EID: 73449101124     PISSN: 17474124     EISSN: None     Source Type: Journal    
DOI: 10.1586/egh.09.60     Document Type: Review

References (70)

1. Szabo E, Lotz G, Paska C, Kiss A, Schaff Z. Viral hepatitis: new data on hepatitis C infection. Pathol. Oncol. Res. 9, 215-221 (2003).
2. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244, 359-362 (1989).
3. Poynard T, Leroy V, Cohard M et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 24, 778-789 (1996).
4. 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 352, 1426-1432 (1998).
5. 2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N. Engl. J. Med. 339, 1485-1492 (1998).
6. 2a for the treatment of hepatitis C. Bioconjug. Chem. 12, 195-202 (2001).
7. Kozlowski A, Charles SA, Harris JM. Development of pegylated interferons for the treatment of chronic hepatitis C. BioDrugs 15, 419-429 (2001).
8. 2b. Biochemistry 39, 10634-10640 (2000).
9. 2b. J. Interferon Cytokine Res. 21, 1103-1115 (2001).
10. 2b. Curr. Pharm. Des. 8, 2139-2157 (2002).
11. 2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347, 975-982 (2002).
12. 2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358, 958-965 (2001).
13. 2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med. 140, 346-355 (2004).
14. 2a plus ribavirin. Gastroenterology 131, 1040-1048 (2006).
15. McHutchison JG, Manns M, Patel K et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 123, 1061-1069 (2002).
16. Herrmann E, Sarrazin C. [Hepatitis C-virus - virus kinetics and resistance mechanisms]. Z. Gastroenterol. 42, 387-396 (2004).
17. Herrmann E, Lee JH, Marinos G, Modi M, Zeuzem S. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology 37, 1351-1358 (2003).
18. 2a. Gastroenterology 120, 1438-1447 (2001).
19. 2a plus ribavirin. Aliment Pharmacol. Ther. 28, 43-50 (2008).
20. Shiffman ML, Salvatore J, Hubbard S et al. Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin α. Hepatology 46, 371-379 (2007).
21. Maynard M, Pradat P, Gagnieu MC, Souvignet C, Trepo C. Prediction of sustained virological response by ribavirin plasma concentration at week 4 of therapy in hepatitis C virus genotype 1 patients. Antivir. Ther. 13, 607-611 (2008). •• Investigates ribavirin (RBV) pharmacokinetics in order to optimize RBV doses and predict the treatment response.
22. Loustaud-Ratti V, Alain S, Rousseau A et al. Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C. Hepatology 47, 1453-1461 (2008). •• Investigates RBV pharmacokinetics in order to optimize RBV doses.
23. 2a/ribavirin treatment. Clin. Gastroenterol. Hepatol. 5, 124-129 (2007).
24. 2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology 132, 103-112 (2007).
25. Dusheiko G, Nelson D, Reddy KR. Ribavirin considerations in treatment optimization. Antivir. Ther. 13(Suppl. 1), 23-30 (2008).
26. Gambarin-Gelwan M, Jacobson IM. Optimal dose of peginterferon and ribavirin for treatment of chronic hepatitis C. J. Viral. Hepat. 15, 623-633 (2008).
27. Martin P, Jensen DM. Ribavirin treatment of chronic hepatitis C. J. Gastroenterol. Hepatol. 23, 844-855 (2008).
28. 2a (40 kd)/ribavirin therapy. Hepatology 43, 954-960 (2006).
29. 2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology 135, 451-458 (2008).
30. Mangia A, Minerva N, Bacca D et al. Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial. Hepatology 47, 43-50 (2008).
31. Yu ML, Dai CY, Huang JF et al. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology 47, 1884-1893 (2008).
32. 2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J. Hepatol. 44, 97-103 (2006).
33. 2a plus ribavirin. Gastroenterology 130, 1086-1097 (2006).
34. 2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 131, 451-460 (2006).
35. Pearlman BL, Ehleben C, Saifee S. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis C genotype 1-infected slow responders. Hepatology 46, 1688-1694 (2007).
36. Buti M, Lurie Y, Zakharova NG et al. Extended treatment duration in chronic hepatitis C genotye 1-infected slow responders: final results of the SUCCESS study (Abstract). J. Hepatol. 50, S58 (2009).
37. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 49, 1335-1374 (2009).
38. Dhumeaux D, Marcellin P, Lerebours E. Treatment of hepatitis C. The 2002 French consensus. Gut 52, 1784-1787 (2003).
39. 2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J. Hepatol. 40, 993-999 (2004).
40. 2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 129, 522-527 (2005).
41. 2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N. Engl. J. Med. 352, 2609-2617 (2005).
42. Yu ML, Dai CY, Huang JF et al. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 56, 553-559 (2007).
43. 2a and ribavirin for 12 or 24 weeks in patients with HCV genotype 2 or 3: the Cleo trial. Hepatology 46 (Suppl.), 1327 (2007).
44. 2b plus ribavirin for HCV genotype 2 patients. Hepatology 48 (Suppl.), 1872 (2008).
45. 2b and ribavirin for 12 versus 24 weeks in HCV genotype 2 or 3. J. Coll. Physicians Surg. Pak. 18, 620-624 (2008).
46. 2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N. Engl. J. Med. 357, 124-134 (2007).
47. 2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. Hepatology 47, 1837-1845 (2008).
48. Dalgard O, Bjoro K, Ring-Larsen H et al. Pegylated interferon a and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. Hepatology 47, 35-42 (2008).
49. 2b plus weight-based ribavirin in European and Asian genotype 2 and 3 chronic hepatitis C (REDD 2/3 trial). J. Hepatol. 50 (Suppl. 1), S59 (2009).
50. 2B (Abstract). J. Hepatol. 50, S232 (2009).
51. 2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 38, 75-85 (2003).
52. 2a (40KD) (PEGASYS) plus Ribavirin (COPEGUS) for 16 or 24 weeks. Liver Int. 29, 237-241 (2009).
53. 2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response. Gut 54, 858-866 (2005).
54. 2b/ ribavirin/amantadine: a non-randomized controlled study. Am. J. Gastroenterol. 100, 2447-2452 (2005).
55. Kamal SM. Hepatitis C genotype 4 therapy: increasing options and improving outcomes. Liver Int. 29(Suppl. 1), 39-48 (2009).
56. Rossignol JF, Elfert A, El-Gohary Y, Keeffe EB. Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin. Gastroenterology 136, 856-862 (2009).
57. 2b plus ribavirin in the retreatment of chronic hepatitis C. Am. J. Gastroenterol. 100, 2453-2462 (2005).
58. 2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 126, 1015-1023; discussion 947 (2004).
59. -2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients. Gastroenterology 130, 1098-1106 (2006).
60. 2b: a randomized trial. Ann. Intern. Med. 150, 528-540 (2009).
61. 2b in prior interferon nonresponders with chronic hepatitis C. Clin. Gastroenterol. Hepatol. 7, 212-218 (2009).
62. Bacon BR, Shiffman ML, Mendes F et al. Retreating chronic hepatitis C with daily interferon acon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results. Hepatology 49, 1838-1846 (2009).
63. Ahmed A, Keeffe EB. Chronic hepatitis C with normal aminotransferase levels. Gastroenterology 126, 1409-1415 (2004).
64. Deltenre P, Canva V, El Nady M et al. A 2-log drop in viral load at 1 month is the best predictor of sustained response in HCV patients with normal ALT: a kinetic prospective study. J. Viral Hepat. 16, 500-505 (2009).
65. McHutchison JG, Everson GT, Gordon SC et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N. Engl. J. Med. 360, 1827-1838 (2009). •• Very important preliminary results for treatment-naive genotype 1 patients.
66. Hezode C, Forestier N, Dusheiko G et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N. Engl. J. Med. 360, 1839-1850 (2009). •• Very important preliminary results for treatment-naive genotype 1 patients.
67. 2b)/ ribavirin in treatment-naive subjects with genotype-1 chronic hepatitis C (Abstract). J. Hepatol. 50(Suppl. 1), S4 (2009). •• Very important preliminary results for naive-treatment genotype 1 patients.
68. 2a/b and ribavirin therapy: PROVE-3 interim results. (Abstract). Hepatology 48, 431-432 (2008). • Very important preliminary results for nonresponder: regarding the use of telaprevir in association with pegylated IFN-α and RBV.
69. Sarrazin C, Kieffer TL, Bartels D et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 132, 1767-1777 (2007).
70. American Association for the Study of Liver Diseases Practice. American Association for the Study of Liver Diseases Practice Guidelines. American Association for the Study of Liver Diseases, VA, USA (2009).